Acuitas Therapeutics, Inc.

Dr. Thomas Madden

President & CEO
Acuitas Therapeutics, Inc.
  • Acuitas Therapeutics works with global partners, from emerging biotechnology firms to pharmaceutical companies to academic institutions and NGOs, to develop new therapies to address unmet clinical needs based on the recognized capabilities of our proprietary best-in-class lipid nanoparticle (LNP) delivery system.
  • Our LNP is clinically validated; it encapsulates and protects the Pfizer/BioNTech COVID-19 vaccine COMIRNATY┬«, which has had billions of doses administered in 180 countries.
  • We are currently working on therapeutics to address cancer, HIV/AIDS, tuberculosis, malaria and other serious diseases.